Icon

ELIQUIS (nda202155)- (2.5MG,5MG)

APIXABAN BRISTOL MYERS SQUIBB
2.5MG,5MG
Yes No
2031-Feb-24 2017-Dec-28
None None
None No
ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.
8 10 1
Total Other Developers 30
Drugs with Suitability No
2.5MG ** ** Up - -
5MG ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ****** ******** ******* *********** *** *****-** & ***, *-**,**,**, ***** ********** ****, *****, ***, *** ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.